Table 1. Baseline characteristics of the study population.
Parameter | n = 467 |
---|---|
Demographics | |
Age (years); Median (IQR) | 49 (45–53) |
Gender; n (%) | |
Male | 352 (75.4) |
HIV risk factors; n (%) | |
IDU | 226 (48.4) |
Heterosexual relations | 91 (19.5) |
MSM | 90 (19.3) |
Bisexual relations | 7 (1.5) |
Other/Unknown | 53 (11.3) |
CD4 and HIV viral load | |
Baseline CD4; median (IQR) | |
CD4 count (cells/μL) | 580 (372–781) |
CD4% | 28 (13) |
Nadir CD4; median (IQR) | 169 (65–274) |
AIDS diagnosis; n (%) | 228 (48.8) |
Time since HIV diagnosis (years); median (IQR) | 17 (10–22) |
Years since undetectable viral load (<50 copies/mL); median (IQR) | 5.2 (2.2–9.9) |
Co-infections; n (%) | |
HBV (HbsAg +) | 14 (3.0) |
HCV (PCR +) | 156 (33.4) |
Reasons for switching; n (%) | |
Drug toxicity/tolerability | 197 (42.2) |
Physician’s criteria* | 133 (28.5) |
Unknown reasons | 123 (26.3) |
Regimen simplification | 38 (8.1) |
Cost reduction————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————- Multiple reasons (toxicity-physician’s criteria; physician’s criteria-other, simplification-other) |
4 (0.9) 28 (6) |
Previous cART; n (%) | |
Single-tablet regimen | |
DGV/ABC/3TC | 3 (0.6) |
RPV/FTC/TDF | 4 (0.9) |
EFV/FTC/TDF | 20 (4.3) |
Non-nucleoside reverse transcriptase inhibitor** | |
RPV | 12 (2.6) |
EFV | 30 (6.4) |
NVP | 18 (3.8) |
ETV | 20 (4.3) |
Protease inhibitor** | |
LPV | 38 (8.1) |
FPV | 31 (6.6) |
ATV unboosted | 65 (13.9) |
ATV boosted | 25 (5.3) |
DRV QD | 47 (10.1) |
DRV BID | 19 (4.07) |
Integrase strand inhibitor** | |
RAL | 118 (25.3) |
Nucleoside reverse transcriptase inhibitor | |
ABC/3TC | 221 (47.3) |
FTC/TDF AZT/3TC/ABC |
124 (26.5) 22 (4.7) |
3TC | 36 (7.7) |
ABC | 11 (2.3) |
FTC | 7 (1.5) |
TDF | 8 (1.7) |
AZT Entry Inhibitors MVC |
21 (4.5) 5 (1.1) |
Monotherapy; n (%) | 18 (3.8) |
LPV/r | 7 (1.5) |
DRV/r | 11 (2.3) |
Dual therapy**; n (%) | 17 (3.6) |
LPV (+3TC: 3; +RAL: 1) DRV/r (+3TC: 4, +RAL: 3; +ETV: 2; +NVP: 1) ATV/r (+3TC: 1) RAL (+DRV/r: 3; +LPV/r: 1; +ETV: 1; +NVP: 1) Switching to RAL 800 mg QD |
4 (0.8) 10 (2.1) 1 (0.2) 6 (1.3) 50 (10.7) |
3TC: lamivudine; ABC: abacavir; AIDS: acquired immunodeficiency syndrome; ATV: atazanavir; AZT: zidovudine; cART: combination antiretroviral therapy; DRV: darunavir; DGV: dolutegravir; EFV: efavirenz, ETV: etravirine; HBV: hepatitis B virus; HCV: hepatitis C virus; FPV: fosamprenavir; FTC: emtricitabine; IDU: injection drug use; LPV: lopinavir; MSM: men who have sex with men; MVC: maraviroc; NVP: nevirapine; RPV: rilpivirine; r: ritonavir; TDF: tenofovir; RAL: raltegravir
* Potential drug interactions, better profile, personal decision
**Dual therapy with 3rd agents.